Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Umeguchi,Hitomi; Sueoka-Aragane,Naoko; Kobayashi,Naomi; Nakamura,Tomomi; Sato,Akemi; Takeda,Yuji; Hayashi,Shinichiro; Sueoka,Eisaburo; Kimura,Shinya

doi:10.3892/or.2014.3560

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Authors:
- Hitomi Umeguchi
- Naoko Sueoka-Aragane
- Naomi Kobayashi
- Tomomi Nakamura
- Akemi Sato
- Yuji Takeda
- Shinichiro Hayashi
- Eisaburo Sueoka
- Shinya Kimura
View Affiliations

Affiliations: Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan, Department of Thoracic Surgery, Faculty of Medicine, Saga University, Saga 849-8501, Japan, Department of Laboratory Medicine, Saga University Hospital, Saga 849-8501, Japan
Published online on: October 22, 2014 https://doi.org/10.3892/or.2014.3560
Pages: 391-396

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Monitoring of molecular markers is indispensable for deciding subsequent treatment after acquired resistance to molecular-targeted therapy. According to results using re-biopsy, EGFR T790M mutation and overexpression of hepatocyte growth factor (HGF) are major mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The aim of the present study was to assess whether quantification of HGF using peripheral blood in addition to detection of T790M with plasma DNA is useful for monitoring as an alternative to invasive re-biopsy. HGF levels in plasma were determined using ELISA and T790M mutation was detected using mutation-biased PCR and quenched probe system (MBP-QP). The median level of HGF in plasma at baseline was 140 pg/ml and was significantly higher in the advanced stage of cancer and in smokers and predicted poor survival as determined using 315 plasma samples from 225 lung cancer patients. T790M was detected with plasma DNA in 9 of 16 patients who acquired resistance to EGFR-TKIs and a greater than 1.5-fold elevation compared with pretreatment HGF levels was observed in 6 patients after acquired resistance. Eleven of 16 patients (69%) showed either HGF elevation or T790M in plasma samples, with both outcomes observed in 25% of patients; this is consistent with results based on re-biopsy reported from other laboratories. Considering these results, assessing HGF and T790M using peripheral blood could be useful for monitoring mechanisms of acquired resistance to EGFR-TKIs.

View Figures

View References

1	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
2	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
3	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
5	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zakowski MF, Ladanyi M and Kris MG: Memorial sloan-kettering cancer center lung cancer oncogenome group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yano S, Wang W, Li Q, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68:9479–9487. 2008. View Article : Google Scholar : PubMed/NCBI
8	Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wang W, Li Q, Takeuchi S, et al: Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 18:1663–1671. 2012. View Article : Google Scholar : PubMed/NCBI
10	Nakagawa T, Takeuchi S, Yamada T, et al: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11:2149–2157. 2012. View Article : Google Scholar : PubMed/NCBI
11	Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
12	Katakami N, Atagi S, Goto K, et al: LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 31:3335–3341. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sequist LV, Pawel J, Garmey EG, et al: Randomised phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 29:3307–3315. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nakamura T, Sueoka-Aragane N, Iwanaga K, et al: A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol. 6:1639–1648. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yano S, Yamada T, Takeuchi S, et al: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
17	Mizuno S and Nakamura T: HGF-MET cascade, a key target for inhibiting cancer metastasis: The impact of NK4 discovery on cancer biology and therapeutics. Int J Mol Sci. 14:888–919. 2013. View Article : Google Scholar : PubMed/NCBI
18	Jiang WG, Martin TA, Parr C, et al: Hepatocyte growth factor, its receptor and their potential value in cancer therapies. Crit Rev Oncol Hematol. 53:35–69. 2005. View Article : Google Scholar
19	Martin TA, Parr C, Davies G, et al: Growth and angiogenesis of human breast cancer in a nude mouse tumor model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis. 24:1317–1323. 2003. View Article : Google Scholar : PubMed/NCBI
20	Wisles M, Rabbe N, Marchal J, et al: Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor progression and death. Cancer Res. 63:1405–1412. 2003.
21	Grenier A, Chollet-Martin S, Crestani B, et al: Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood. 99:2997–3004. 2002. View Article : Google Scholar : PubMed/NCBI
22	Goldstrow P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar
23	Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar
24	Takanami I, Tanana F, Hashizume T, et al: Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Oncology. 53:392–397. 1996. View Article : Google Scholar : PubMed/NCBI
25	Siegfried JM, Weissfeld LA, Luketich JD, et al: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg. 66:1915–1918. 1998. View Article : Google Scholar
26	Toiyama Y, Miki C, Inoue Y, et al: Serum hepatocyte growth factor as a prognostic marker for stage I or II colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009. View Article : Google Scholar : PubMed/NCBI
27	Tanaka K, Miki C, Wakuda R, et al: Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol. 8:754–760. 2004. View Article : Google Scholar
28	Gupta A, Karakiewicz PI, Roehrborn CG, et al: Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14:7385–7390. 2008. View Article : Google Scholar : PubMed/NCBI
29	Seidel C, Borset M, Turesson I, et al: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 91:1806–1812. 1998.
30	Arcila MA, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 17:1169–1180. 2011. View Article : Google Scholar : PubMed/NCBI
31	Suda K, Murakami I, Katayama, et al: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI